Tags

Type your tag names separated by a space and hit enter

Correction to: Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine.
Adv Ther. 2020 Feb; 37(2):973.AT

Abstract

There are some corrections in the original article, Page 11, "/LYXUMIA" word has to be removed from the section RATIONALE FOR COMBINATION THERAPY COMPRISING GLP-1 RAs AND BASAL INSULIN.

Authors+Show Affiliations

Metabolic Institute of America, 18372 Clark St. Suite 212, Tarzana, CA, 91356, USA. yhandelsman@gmail.com.Diabetes Center, Department of Internal Medicine, Amsterdam University Medical Centers (Location VUMC), 1081 HV, Amsterdam, The Netherlands.Department of Medicine, The University of British Columbia, 2775 Laurel Street, Vancouver, BC, V5Z1M9, Canada.

Pub Type(s)

Published Erratum

Language

eng

PubMed ID

31873867

Citation

Handelsman, Yehuda, et al. "Correction To: Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults With Type 2 Diabetes: Focus On Lixisenatide and Insulin Glargine." Advances in Therapy, vol. 37, no. 2, 2020, p. 973.
Handelsman Y, Muskiet MHA, Meneilly GS. Correction to: Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine. Adv Ther. 2020;37(2):973.
Handelsman, Y., Muskiet, M. H. A., & Meneilly, G. S. (2020). Correction to: Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine. Advances in Therapy, 37(2), 973. https://doi.org/10.1007/s12325-019-01185-0
Handelsman Y, Muskiet MHA, Meneilly GS. Correction To: Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults With Type 2 Diabetes: Focus On Lixisenatide and Insulin Glargine. Adv Ther. 2020;37(2):973. PubMed PMID: 31873867.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Correction to: Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine. AU - Handelsman,Yehuda, AU - Muskiet,Marcel H A, AU - Meneilly,Graydon S, PY - 2019/12/25/pubmed PY - 2019/12/25/medline PY - 2019/12/25/entrez SP - 973 EP - 973 JF - Advances in therapy JO - Adv Ther VL - 37 IS - 2 N2 - There are some corrections in the original article, Page 11, "/LYXUMIA" word has to be removed from the section RATIONALE FOR COMBINATION THERAPY COMPRISING GLP-1 RAs AND BASAL INSULIN. SN - 1865-8652 UR - https://www.unboundmedicine.com/medline/citation/31873867/Correction_to:_Combining_GLP-1_Receptor_Agonists_and_Basal_Insulin_in_Older_Adults_with_Type_2_Diabetes:_Focus_on_Lixisenatide_and_Insulin_Glargine L2 - https://dx.doi.org/10.1007/s12325-019-01185-0 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.